Celldex Therapeutics Profit Margin

The latest profit margin for CLDX is -275986.61% as of September 2026. That compares with -8635.85% in the prior-year period — down 3095.8% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Celldex Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CLDX's profit margin moved from -8635.85% to -275986.61% — a 3095.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Celldex Therapeutics's valuation or profitability profile.

Against Healthcare companies, CLDX currently prints -275986.61% for profit margin, while the sector average sits near 9.48%. That is roughly 2911055.6% below the sector mean. Large gaps often invite a closer look at Celldex Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Celldex Therapeutics converts resources into returns. At -275986.61%, CLDX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -8635.85% in the prior-year period — down 3095.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CLDX's profit margin (-275986.61%), review year-over-year change from -8635.85%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.